Percutaneous, Imaging-Guided Biopsy of Bone Metastases
AbstractApproximately 70% of cancer patients will eventually develop bone metastases. Spine, due to the abundance of red marrow in the vertebral bodies and the communication of deep thoracic-pelvic veins with valve-less vertebral venous plexuses, is the most common site of osseous metastatic disease. Open biopsies run the risk of destabilizing an already diseased spinal or peripheral skeleton segment. Percutaneous biopsies obviate such issues and provide immediate confirmation of correct needle location in the area of interest. Indications for percutaneous bone biopsy include lesion characterization, optimal treatment and tumor recurrence identification, as well as tumor response and recurrence rate prediction. Predicting recurrence in curative cases could help in treatment stratification, identification, and validation of new targets. The overall accuracy of percutaneous biopsy is 90–95%; higher positive recovery rates govern biopsy of osteolytic lesions. The rate of complications for percutaneous biopsy approaches is <5%. The purpose of this review is to provide information about performing bone biopsy and what to expect from it as well as choosing the appropriate imaging guidance. Additionally, factors governing the appropriate needle trajectory that would likely give the greatest diagnostic yield and choice of the most appropriate biopsy system and type of anesthesia will be addressed. View Full-Text
Share & Cite This Article
Filippiadis, D.; Mazioti, A.; Kelekis, A. Percutaneous, Imaging-Guided Biopsy of Bone Metastases. Diagnostics 2018, 8, 25.
Filippiadis D, Mazioti A, Kelekis A. Percutaneous, Imaging-Guided Biopsy of Bone Metastases. Diagnostics. 2018; 8(2):25.Chicago/Turabian Style
Filippiadis, Dimitrios; Mazioti, Argyro; Kelekis, Alexios. 2018. "Percutaneous, Imaging-Guided Biopsy of Bone Metastases." Diagnostics 8, no. 2: 25.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.